ABSTRACT
BACKGROUND: Genital psoriasis (GenPs) is a common, debilitating and difficult-to-treat manifestation of plaque psoriasis. However, few controlled, interventional studies of GenPs exist. OBJECTIVES: To determine the efficacy of ixekizumab vs. placebo in patients with moderate-to-severe GenPs with ≥ 1% involved body surface area (BSA). METHODS: Patients with moderate-to-severe GenPs, defined as a baseline static Physician's Global Assessment of Genitalia (sPGA-G) score of ≥ 3, with BSA ≥ 1% were randomized 1 : 1 to receive placebo (n = 74) or the recommended dosing of ixekizumab (n = 75). Major outcomes included the percentage of patients achieving 0 or 1 scores on the sPGA-G (primary end point), overall sPGA, GenPs Sexual Frequency Questionnaire (GenPs-SFQ) item 2, and ≥ 3-point improvement from baseline on the GenPs itch numerical rating scale. RESULTS: At week 12, ixekizumab was superior to placebo for sPGA-G 0/1 (73% vs. 8%, P < 0·001), overall sPGA 0/1 (73% vs. 3%, P < 0·001), GenPs-SFQ item 2 score of 0 or 1 (78% vs. 21%, P < 0·001) and genital itch (60% vs. 8%, P < 0·001). No candidiasis was reported, no deaths occurred and one (1%) serious adverse event was reported in a patient receiving placebo. CONCLUSIONS: Ixekizumab was superior to placebo for the treatment of moderate-to-severe GenPs with BSA ≥ 1%. The safety profile of ixekizumab was consistent with previous studies in moderate-to-severe plaque psoriasis.
Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Dermatologic Agents/administration & dosage , Pruritus/drug therapy , Psoriasis/drug therapy , Adult , Antibodies, Monoclonal, Humanized/adverse effects , Dermatologic Agents/adverse effects , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Genitalia , Humans , Injections, Subcutaneous , Male , Middle Aged , Placebos/administration & dosage , Placebos/adverse effects , Pruritus/diagnosis , Pruritus/etiology , Psoriasis/complications , Psoriasis/diagnosis , Psoriasis/psychology , Quality of Life , Severity of Illness Index , Sexual Health , Treatment OutcomeABSTRACT
BACKGROUND: The 585-nm pulsed-dye laser is the treatment of choice for many port-wine stains. The risk of accidental flash fires occurring with the pulsed-dye laser is considered minimal. Recently, however, there have been several reports of unwanted ignitions. These cases all share two features: 1) oxygen delivery by face mask, and 2) the ignition of a hair-bearing surface. OBJECTIVE: We report a case of a laser-induced fire that occurred on a non-hair-bearing surface in a patient who was receiving oxygen by nasal cannula. The mechanisms, risk factors, and guidelines for the prevention of pulsed-dye laser-induced fires are presented. METHODS: We reviewed the literature regarding the safety of pulsed-dye laser use. RESULTS: Pulsed-dye laser-induced fires can occur on non-hair-bearing regions and in patients receiving oxygen by nasal cannula. CONCLUSION: Precautions should be taken to prevent pulsed-dye laser fires regardless of treated region or method of oxygen delivery.
Subject(s)
Burns/etiology , Facial Dermatoses/radiotherapy , Fires , Hamartoma/radiotherapy , Lasers/adverse effects , Child , Facial Injuries/etiology , Humans , Male , Safety ManagementABSTRACT
Eccrine syringofibroadenoma (acrosyringeal nevus) is a rare tumor of proliferating ductular structures resembling the acral portion of the eccrine duct. Our case describes a histologic variant showing nests of periodic acid Schiff-positive clear cells resembling the clear-cell variant of eccrine syringoma.
Subject(s)
Adenoma, Sweat Gland/pathology , Fibroadenoma/pathology , Sweat Gland Neoplasms/pathology , Aged , Aged, 80 and over , Cell Division , Coloring Agents , Cytoplasm/ultrastructure , Diagnosis, Differential , Eccrine Glands/pathology , Epidermis/pathology , Female , Humans , Periodic Acid-Schiff Reaction , Syringoma/pathologyABSTRACT
A cDNA encoding an H3.3 histone variant in Drosophila melanogaster predicts a protein with an amino acid (aa) sequence identical with that in vertebrates. The D. melanogaster H3.3 nucleotide (nt) sequence has diverged significantly from that of both the H3.3 gene of vertebrates and the H3.1 gene of D. melanogaster, largely through third nt changes in its codons. The perfect H3.3 aa sequence conservation between organisms as phylogenetically divergent as vertebrates and flies suggests that the H3.3 histone variant itself is an important structural component of chromatin, apart from the value of its replication-independent expression pattern.